Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
Tonsillitis II: Management01:26

Tonsillitis II: Management

This lesson will focus on the different treatment options for managing tonsillitis, which typically depend on the cause and severity.
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Non-Aspergillus fumigatus mould infections in lung transplant recipients: an international, multicentre, case-control study.

The Lancet. Microbe·2026
Same author

A Randomized Trial of Interval Likelihood Ratios for Clinical Decision-Making.

NEJM evidence·2026
Same author

A Coaching-Centered Inpatient Rotation Fosters Growth Mindset and Deliberate Practice in Resident Physicians.

Journal of graduate medical education·2026
Same author

An Update on Invasive Fungal Infections in Solid Organ Transplant Recipients.

Transplant infectious disease : an official journal of the Transplantation Society·2026
Same author

Synthesis of desloratadine analogues as potent antifungal agents: in vitro and in vivo efficacy, and structure-activity relationship studies.

Bioorganic chemistry·2026
Same author

Lung Biopsies in Patients Referred for Allogeneic Hematopoietic Cell Transplantation: Diagnostic Accuracy, Diagnostic Yield, and Clinical Utility.

Transplant infectious disease : an official journal of the Transplantation Society·2026

関連する実験動画

Updated: Jul 24, 2026

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

急性支氣管炎に対するアジトロマイシン:ランダム化,ダブルブラインド,制御試験.

Arthur T Evans1, Shahid Husain, Lakshmi Durairaj

  • 1Collaborative Research Unit, Department of Medicine, Cook County Hospital and Rush Medical College, Chicago, IL 60612, USA. aevans@cchil.org

Lancet (London, England)
|May 22, 2002
PubMed
まとめ

アジトロマイシンは,急性支障管炎の治療にビタミンCよりも利点がありません. この一般的な呼吸器疾患の最適な管理を決定するために,さらなる研究が必要である.

さらに関連する動画

Isolated Lung Perfusion System in the Rabbit Model
10:18

Isolated Lung Perfusion System in the Rabbit Model

Published on: July 15, 2021

Experimental Model to Evaluate Resolution of Pneumonia
09:49

Experimental Model to Evaluate Resolution of Pneumonia

Published on: February 17, 2023

関連する実験動画

Last Updated: Jul 24, 2026

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

Isolated Lung Perfusion System in the Rabbit Model
10:18

Isolated Lung Perfusion System in the Rabbit Model

Published on: July 15, 2021

Experimental Model to Evaluate Resolution of Pneumonia
09:49

Experimental Model to Evaluate Resolution of Pneumonia

Published on: February 17, 2023

科学分野:

  • 呼吸器医学とは
  • クリニック・トライアル 臨床試験
  • 薬理学 薬理学とは

背景:

  • 急性支氣管炎は,アジトロマイシンの有効性を裏付ける証拠が不足しているにもかかわらず,アジトロマイシンで頻繁に治療されています.
  • 急性支氣管炎に対するアジトロマイシンの有効性は,厳格な臨床試験ではほとんど調査されていません.

研究 の 目的:

  • 急性支末炎の治療におけるアジトロマイシンの有効性をビタミンCと比較して評価する.
  • 急性支氣管炎患者の健康関連の生活の質への影響を評価する.

主な方法:

  • 急性肺炎と診断された成人を対象に,ランダム化,ダブルブラインド,制御試験が行われました.
  • 参加者はアジトロマイシンまたはビタミンCを5日間,デクストロメソルファンとアルブテロールと共に投与された.
  • 測定された主なアウトカムは,7日後の健康関連の生活の質の改善であり,治療の意図によって分析されました.

主要な成果:

  • アジトロマイシンは,ビタミンCと比較して7日後に健康関連の生活の質の有意な改善を示さなかった (差異0.03,p=0.8).
  • 7日目までに通常の活動への復帰は,グループ間 (89%),統計的に有意な差異はありませんでした.
  • 副作用の頻度は比較可能で,ビタミンC群では,副作用が認められたため中止がわずかに多かった.

結論:

  • アジトロマイシンは,急性支障管炎の治療において,低用量ビタミンCに優れているわけではありません.
  • 急性支氣管炎の最も効果的な治療戦略を確立するために,さらなる研究が必要である.